Low-density lipoprotein apheresis and changes in plasma components

被引:18
作者
Kojima, S [1 ]
机构
[1] Tohsei Natl Hosp, Dept Clin Res, Shimizu, Shizuoka 4118611, Japan
来源
THERAPEUTIC APHERESIS | 2001年 / 5卷 / 04期
关键词
amyloidosis; bradykinin; hypercholesterolemia; low-density lipoprotein apheresis lipoprotein (a);
D O I
10.1046/j.1526-0968.2001.00344.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Several different techniques of low-density lipoprotein (LDL) apheresis are available for management of severe hypercholesterolemia. Among them, the adsorption system with a dextran-sulfate cellulose (DSC) column is most widely used. In addition to adsorption of LDL, DSC adsorbs plasma constituents that have the following characteristics: proteins containing apolipoprotein B (Lp[a]): proteins involved in the initial contact phase of the intrinsic coagulation pathway (coagulation factor XII, high-molecular-weight kininogen and prekallikrein): factors with lipophilic characteristics (coagulation factor VII, coagulation factor VIII, and vitamin E): and proteins with adhesive or other characteristics (on Willebrand factor, fibronectin, serum amyloid P component, hepatocyte growth factor). The adsorption of these proteins seems to ameliorate prevention or regression of atherosclerosis. Moreover, plasma treatment by the DSC column may be useful for treatment of inexorable diseases, such as amyloidosis. On the other hand, the DSC column generates bradykinin by activation of the initial contact phase of the intrinsic coagulation pathway. Bradykinin generation may explain the functional improvement in the circulatory system. as well as hypotension during LDL apheresis, which is observed in patients taking ACE inhibitors.
引用
收藏
页码:232 / 238
页数:7
相关论文
共 28 条
[1]  
AGISHI T, 1980, T AM SOC ART INT ORG, V26, P406
[2]   PHARMACOLOGICAL STUDIES OF FUT-175, NAFAMSTAT MESILATE .1. INHIBITION OF PROTEASE ACTIVITY IN INVITRO AND INVIVO EXPERIMENTS [J].
AOYAMA, T ;
INO, Y ;
OZEKI, M ;
ODA, M ;
SATO, T ;
KOSHIYAMA, Y ;
SUZUKI, S ;
FUJITA, M .
JAPANESE JOURNAL OF PHARMACOLOGY, 1984, 35 (03) :203-227
[3]  
BERG K, 1974, CLIN GENET, V6, P230
[4]  
BOSCH T, 1993, ARTIF ORGANS, V17, P640
[5]   HEPATOCYTE GROWTH-FACTOR IS A POTENT ANGIOGENIC FACTOR WHICH STIMULATES ENDOTHELIAL-CELL MOTILITY AND GROWTH [J].
BUSSOLINO, F ;
DIRENZO, MF ;
ZICHE, M ;
BOCCHIETTO, E ;
OLIVERO, M ;
NALDINI, L ;
GAUDINO, G ;
TAMAGNONE, L ;
COFFER, A ;
COMOGLIO, PM .
JOURNAL OF CELL BIOLOGY, 1992, 119 (03) :629-641
[6]   SELECTIVE REMOVAL OF LOW-DENSITY LIPOPROTEINS (LDL) BY PRECIPITATION AT LOW PH - 1ST CLINICAL-APPLICATION OF THE HELP SYSTEM [J].
EISENHAUER, T ;
ARMSTRONG, VW ;
WIELAND, H ;
FUCHS, C ;
SCHELER, F ;
SEIDEL, D .
KLINISCHE WOCHENSCHRIFT, 1987, 65 (04) :161-168
[7]  
FURCHGOTT RF, 1981, TRENDS PHARMACOL SCI, V3, P175
[8]   LIPOPROTEIN(A) MODULATION OF ENDOTHELIAL-CELL SURFACE FIBRINOLYSIS AND ITS POTENTIAL ROLE IN ATHEROSCLEROSIS [J].
HAJJAR, KA ;
GAVISH, D ;
BRESLOW, JL ;
NACHMAN, RL .
NATURE, 1989, 339 (6222) :303-305
[9]  
JOVIN IS, 1995, LANCET, V346, P117
[10]   LIPOPROTEIN(A) IN ISCHEMIC CEREBROVASCULAR-DISEASE - A NEW APPROACH TO THE ASSESSMENT OF RISK FOR STROKE [J].
JURGENS, G ;
KOLTRINGER, P .
NEUROLOGY, 1987, 37 (03) :513-515